🚀 A milestone moment in lipid therapeutics!
The new JAMA trial on the oral PCSK9 inhibitor Enlicitide reports a ~60% reduction in LDL-C, with parallel decreases in ApoB and Lp(a)—all on top of maximally tolerated statin therapy.
For individuals with heterozygous familial hypercholesterolemia (HeFH)—where reaching LDL targets remains a persistent challenge—this represents a major advance. An oral agent matching the potency of injectable PCSK9 inhibitors could reshape adherence, access, and long-term ASCVD prevention. 🌉💊
Safety was comparable to placebo, and effects were rapid, robust, and sustained to 52 weeks. The ongoing CORALreef Outcomes trial will determine its impact on major cardiovascular events. 🔬❤️
Innovation in lipid lowering is accelerating—and patient-centered options are expanding.
#JAMA #LipidManagement #HeFH #CardiovascularHealth #PCSK9 #Enlicitide #Prevention 🌟
